Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare


Charles River Discovery




Silicon Biosystems   




  View All Sponsors 

2013 Archived Content
Second Annual

Bioinformatics in the Genome Era

Understanding the Evolving Role of Bioinformatics in Molecular Medicine


Day 1 | Day 2 | Day 3 | View TRICON Attendees 

Explosive growth of biological information has resulted from many advances in the field of molecular biology and sophisticated techniques and equipment used to carry out rapid genome sequencing. These advances have enabled improvement in biological research and clinical medicine. For example, scientists are able to find cures for some hereditary or acquired diseases and cancers by viewing or analyzing genes directly related to them. Through the use of computational simulation and network modeling, the molecular basis of a disease can be observed. Drugs can then be designed that target those genes which are diseased. Thought leaders will present how bioinformatics is being integrated and applied to real scientific or research problems that drug discovery/development typically face and how its application has impacted them.

Wednesday, February 13

7:00 am Registration and Morning Coffee


Plenary Keynote Session 

8:00 – 9:40 am Plenary Keynote Presentation - Personalized Oncology – Fulfilling the Promise for Today's Patients

In honor of the 20th anniversary of the Molecular Medicine Tri-Conference, CHI and Cancer Commons will present a plenary panel on Personalized Oncology. Innovations such as NGS and The Cancer Genome Atlas have revealed that cancer comprises hundreds of distinct molecular diseases. Early clinical successes with targeted therapies suggest that cancer might one day be managed as a chronic disease using an evolving cocktail of drugs.Representing all five conference channels, Diagnostics, Therapeutics, Clinical, Informatics, and Cancer, a panel of experts will lead a highly interactive exploration of what it will take to realize this vision in the near future.

Read more 

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing


NGS Platforms and Workflows: Data Analysis and Implementation 

11:00 Chairperson’s Opening Remarks

11:10 The Impact of Novel Sequencing Technologies on Antibody Discovery and Development

Jacob Glanville, Ph.D., Science Director, Distributed Bio

11:40 From Data to Discovery: Case Studies, Lessons Learned, and Next Steps

Joseph Szustakowski, Ph.D., Senior Group Head, Bioinformatics, Biomarker Discovery, Novartis Institutes for BioMedical Research

This presentation will describe several case studies to highlight the bioinformatics challenges we face when analyzing NGS data, the computational infrastructure required to enable such analyses, and the analysis algorithms and strategies used to solve the problems at hand.

12:10 pm Toward an Open Translational Research System: Leveraging tranSMART to Drive the Management of Clinical and Molecular Information

Jay Bergeron, Program Manager, Pfizer

Appistry12:40 Luncheon Presentation I: Scaling Science for Performance: Implementing a Cost-Effective "Big Data" Environment for Genetic AnalysisGordon Springer, Ph.D., Scientific Director, Computer Science, University of Missouri Bioinformatics Consortium"Fabric computing" has enabled a leading agricultural genomics research consortium to scale automated sequencing pipelines and alleviate the data management burden associated with traditional high-performance computing architectures. The environment facilitates research collaborations by enabling scientists to rapidly and cost effectively develop custom pipelines using their preferred bioinformatics tools.

Cycle Computing1:10 Luncheon Presentation II: Impossibly Large Database Modeling, Made Possible with Utility SupercomputingJason Stowe, CEO, Cycle Computing This talk will discuss real world use cases for molecular modeling and genomics using very large databases on utility supercomputers. We'll cover historical and present analysis being done using Cycle software for small and large organizations, from Schrodinger to Novartis to the Morgridge Institute for Research, that yield viable compounds in the wetlab that would otherwise not have been found.

1:45 20th Anniversary Cake in the Exhibit Hall with Poster Viewing 


Integrating Genomic Information 

2:15 Chairperson’s Remarks
Tibor van Rooij, Ph.D. Candidate, Pharmacy and Pharmaceutical Sciences, University of Alberta; former Director of Bioinformatics, Génome Québec and Montreal Heart Institute Pharmacogenomics Centre 

2:20 Integrative Omics Profiling for Personalized Medicine

Rui Chen, Ph.D., Postdoctoral Scholar, Snyder Lab, Department of Genetics, Stanford University School of Medicine

We performed an integrative Personal Omics Profile (iPOP) analysis on one volunteer individual over a 14-month period, combining multiple omics information collected from 20 time points. We observed extensive, dynamic molecular changes across various physiological stages.

2:50 Interactive Medical Decision Trees: Using Up-to-Date Genomics and IT to Bring Personalized Care to Regional Populations

Tibor van Rooij, Ph.D. Candidate, Pharmacy and Pharmaceutical Sciences, University of Alberta; former Director of Bioinformatics, Génome Québec and Montreal Heart Institute Pharmacogenomics Centre

Learn about an innovative approach which uses available genomics data, newly collected data from pgeni.org and its nine affiliated centers worldwide and de-novo generated medical decision trees. This approach allows for personalized medicine at point-of-care for use by country-specific healthcare systems.

3:20 Systems Biology Approaches for Identifying Biomarkers, Drug Targets and Predicting Outcomes in Complex Diseases

Gürkan Bebek, Ph.D., Instructor (Faculty of Medicine), Case Center for Proteomics and Bioinformatics, Case Western Reserve University; Visiting Scientist, Genomic Medicine Institute, Cleveland Clinic 

The talk discusses integrative -omics analysis approaches that has been developed to tackle problems in complex diseases such as colorectal cancer, glioblastoma multiforme and Alzheimer's disease. Large-scale molecular characterization of tissue samples are integrated using novel systems biology approaches to identify biomarkers, drug targets for further studies and predict outcomes. These approaches provide new venues for understanding complex human genetic diseases.

Ingenuity3:50 Transcriptomics Analysis of Human Muscle Redefines mTOR Role in Growth RegulationJamie Timmons, Ph.D., Professor, Systems Biology, Loughborough UniversityTranscriptomics analysis has evolved to the point that robust experiments can be done in-silico. Using Upstream Regulator Analysis in Ingenuity's IPA, we analyzed human clinical samples and discovered mTor is a new molecular regulator of human muscle growth.

4:20 Networking Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunities Available) 

5:20 Breakout Discussions in the Exhibit Hall

Business Intelligence (BI) in Biomedical Research
Moderator: Harpeet, Singh, Ph.D., Scientist, Indian Council of Medical Research
-Definition of Business Intelligence (BI) for Biomedical Research
-Potential applications of BI in Biomedical Research such as data integration, evidence based drug discovery, text mining, quantitative identification of expertise
-Is BI a potential solution for major challenges of Bioinformatics?
-Challenges for using BI in Biomedical Research

Metabolism and Nutrition 
Moderator: Cindy Crowninshield, RD, LDN, Dietitian, Body Therapeutics; Founder, Eat2BeWell and Eat4YourGenes; Conference Director, Cambridge Healthtech  Institute 
-Molecular mechanisms of metabolism and metabolic disease as related to human nutrition 
-Interaction of nutrition, epigenetics and human health 
-Discuss educational programming opportunities on molecular nutrition that can be offered at future Tri-conferences 

Developing a Rapid Learning Community for Cancer

Moderator: Marty Tenenbaum, Ph.D., Founder & Chairman, Cancer Commons; AI Researcher; Ecommerce Pioneer; and Cancer Survivor

Sarah Greene, Executive Director, Cancer Commons; formerly Editor of The Scientist and Faculty of 100

-Developing a rapid learning community for cancer
-Data and knowledge sharing initiatives needed
-Translating biomarker drive cancer treatments into practice

6:20 Close of Day


Day 1 | Day 2 | Day 3